Hospital Universitario De Cabuenes — Clinical Trial Site

49 Registered trials

21 Currently recruiting

Organisation

Hospital Universitario De Cabuenes

Location

Gijon, Spain

Identifier

ORG-100043970

Address

Calle Prados 395, Cabuenes, 33394, Spain

Departments

#2310:servicio de neurología
CARDILOGY
Cardiology
Digestive
Digestivo
ES10019: Hematología
Gastroenterology
Hematology
Hematology Service
Hospital de Cabueñes, Gijón
Nefrology
Oncology
Servicio de Aparato Digestivo
Servicio de Cardiologia
Servicio de Endocrinologia
Servicio de Hematologia
Surgery
Unidad de Enfermedad Inflamatoria Intestinal

Clinical trials at this site (49)

Search interface

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending

2025-524181-26-00 relapsed/refractory multiple myeloma 4
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting

2025-521038-27-00 Immune system diseases 5 2026-06-23
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Recruiting

2025-523117-28-00 Relapsed or Refractory Multiple Myeloma 4 2026-06-12
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5 2026-05-28
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting

2024-512436-29-00 CARDIOVASCULAR DISEASES 11 2026-03-27
CROSS-OVER ANALYSIS OF THE CONTROL OF RISK FACTORS AND ANTIAGGREGATION WITH POLIPILL (POLICROSS TRIAL) Recruiting

2024-518705-18-00 Degree of control coronary risk factors and platelet ag 11 2026-03-27
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting

2025-521152-34-00 mantle cell lymphoma (MCL) 4 2025-09-04
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Multiple myeloma 5 2025-04-30
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting

2023-505868-11-00 CHRONIC RENAL DISEASE 5 2025-01-17
A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting

2023-505242-25-00 High-Risk Monoclonal Gammopathy of Undetermined Signifi 4 2024-11-05
Short-term interruption versus continuous anticoagulation in colorectal polypectomy. A randomized multicenter investigator-initiated non-inf… Recruiting

2024-512194-27-01 Patients receiving oral anticoagulant therapy who are s 6 2024-10-21